Dr. Bradley Cameron Ekstrand, MD, PhD

Dr. Ekstrand practices at California Cancer Care a Medical Group Inc in San Mateo, California.

Dr. Ekstrand's NPI, 1528125135, was assigned on January 2, 2007. Dr. Ekstrand graduated from Yale School of Medicine in 1997. Dr. Ekstrand holds California license A71243.

Dr. Ekstrand's primary practice is California Cancer Care a Medical Group Inc, at 218 De Anza Blvd, San Mateo, CA 94402 in San Mateo County. The practice phone is (650) 341-9131.

Dr. Ekstrand's primary practice is California Cancer Care a Medical Group Inc in San Mateo, California. Dr. Ekstrand is also affiliated with Stanford Hospital at 300 Pasteur Drive. The medical group on file is UCSF Medical Group. Dmand AI also links Dr. Ekstrand to 3 more hospitals, 2 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ekstrand practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ekstrand's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ekstrand is board certified in medical oncology by the American Board of Internal Medicine. Dr. Ekstrand is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Ekstrand treats.

CMS data shows 40,748 Medicare services from Dr. Ekstrand across 35 procedure codes in 2024, for 454 Medicare patients. Medicare paid $1,665,791 for them.

CMS counts 454 Medicare patients who saw Dr. Ekstrand in 2024. The largest group is 75 to 84, with 185 patients. 74% of them have high blood pressure, and 74% have high cholesterol. 3% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ekstrand's median patient age at 76, with 33% women.

In 2024, Dr. Ekstrand wrote 1,366 Medicare Part D claims for 202 patients. 77% of them were for generic drugs. CMS names the drug for 1,188 of them, across 29 drugs with 11 or more claims each, at $4,097,634 in total drug cost. In 2023, CMS named 887 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Ekstrand for performance year 2024, reported as part of a group. Dr. Ekstrand accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ekstrand as offering telehealth.

Dmand AI links 6 papers to Dr. Ekstrand in 2003. The most frequent topics are Genes, DCC, Base Sequence and Gene Expression Regulation, Neoplastic. Dr. Ekstrand's most frequent co-authors are Nancy Lee Bartlett, MD, Richard Thomas Hoppe, MD and Steven Mankowitz Horwitz, MD.

CMS Open Payments shows 95 general payments to Dr. Ekstrand from 31 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 80% of the total. Pfizer Inc. paid the most, $433.

Dmand AI lists 1 award for Dr. Ekstrand, most recently CMS Stage 1 EHR in 2013.

Dr. Ekstrand graduated from Yale School of Medicine in 1997. Dr. Ekstrand is a member of ASCO.

Dr. Ekstrand is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.